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The recently created French Study Group for Large Vessel
asculitis (GEFA, “Groupe d’Étude Franc¸ ais des Artérites des gros
aisseaux”) is a multidisciplinary panel comprised of members
ommitted to the care and study of patients with giant cell arteri-
is (GCA). While our understanding of the vasculitides has grown,
uch remains unknown. Treatment is not curative and is associ-
ted with signiﬁcant morbidity [1]. In hoping to inform and guide
ractitioners, GEFA members have attempted to achieve at least
0% consensus on recommendations for nomenclature, diagnosis
nd treatment. For each of these topics there exists varying degrees
f controversy, making a rigorous examination of available data
nd provision of sound advice especially welcome. The iterative,
onsensus-seeking approach taken by GEFA members has been
uccessful and is an important contribution for guiding medical
ractice. In a ﬁeld that thankfully continues to evolve, GEFA authors
ave been cautious to indicate that their judgments and recom-
endations are provisional and should be updated over time. In
hat vein, this important paper also provides the reader with a com-
ass to conceive of future work that will enrich the state of the art
f large vessel vasculitis (LVV).
In regard to diagnostic recommendations, the authors’ review
ncludes 2 studies that address the utility of clinical features
ighly suggestive of GCA, and that were also predictive of a
ositive temporal artery (TA) biopsy. The presence of masseter
uscle claudication, diplopia, new onset uncharacteristic/atypical
eadaches and temporal artery abnormalities on physical examina-
ion signiﬁcantly increased the probability of a positive TA biopsy.
ombinations of features such as polymyalgia rheumatic (PMR),
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mal  TA examination ﬁndings conferred a positive predictive value
of 97% and a positive likelihood ratio of 47 to support a diagnosis of
GCA; and disease onset after 70 years of age increased the positive
predictive value to 100%. While these associations were only seen
in 27% of the patients with PMR, the data would suggest that a TA
biopsy (yield for positives being 49–85%) in such patients is likely
unnecessary and may  even be potentially misleading, encouraging
some less experienced practitioners to not treat a patient with con-
vincing clinical evidence of GCA if their biopsy was negative. The
cost-effectiveness of a “no-biopsy strategy” in such patients could
be assessed with long-term follow up to determine how often such
patients with compelling, high probability presentations were later
diagnosed with an illness other than GCA.
GEFA provides an excellent review and recommendations for
different modes of large vessel imaging. While it is possible to com-
pare the diagnostic performance of imaging of a TA to results of
biopsies, pathology–imaging correlations are less feasible for LVV.
Pathology–imaging correlation studies with substantial numbers
of patients have not been produced for large vessel disease in GCA
or other forms of LVV. Consequently, questions about ﬁndings such
as vessel wall thickening or enhancement being either a reﬂection
of active disease vs damage (e.g. hypertrophy-myointimal prolifer-
ation and neovascularization from in-growth of the vasa-vasorum)
remain unanswered. Multicenter, prospective studies of patients
with possible aortitis and thoracic aortic aneurysms, having PET-
CT or MRI/MRA scans prior to aortic reconstruction surgery could
answer questions about pathology–imaging correlations.How often is LVV a component of GCA? The answer to that ques-
tion is a matter of perspective. If one looks for LVV in GCA by only
clinical features, the yield is about 25% [2–4]. However, if one’s
screening tool is imaging of consecutive GCA patients, it is much
y Elsevier Masson SAS. All rights reserved.
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igher (77% by CT angiography prior to treatment; similar stud-
es with PET/CT have not been done) [5]. If the frequency of LVV is
ssessed in consecutive post-mortem patients with GCA it is 100%
6]. These data indicate that LVV is common and mostly subclini-
al in GCA. Nonetheless, it is important for the following reason.
hile arguments can be made for the mortality of patients with
CA being no greater than in an age- and gender-matched popu-
ation, it is clear that mortality is increased in patients in whom
CA has produced a thoracic aortic aneurysm. Such patients have
p to a 50% risk of aneurysm rupture, dissection and sudden death.
f one accepts this data, then we should all agree that every patient
ith GCA should be screened for LVV. How then should screening
roceed? How cost-effective would it be to evaluate GCA patients
ith 4 extremity pulse and blood pressure measurements; to listen
or bruits over large vessels or at least the thoracic aorta and aortic
alve; or obtain an imaging study with low risk of ionizing radiation
e.g. US of aortic valve and root/arch or MRA/MRI in patients with
ormal renal function)? While we await concrete data to answer
hese questions, it is clear that the cost of the afore-mentioned
linical assessment is a modest amount of examination time and
hould be endorsed. Recognizing that the data is incomplete, GEFA
ecommends “CT or MRI  screening for complications of aortitis at
iagnosis, then every 2–5 years, provided the patient has no con-
raindications to a potential aorta repair.” The latter would be the
nly life-saving intervention in the setting of a dangerously large or
apidly expanding aneurysm. This GEFA recommendation is quite
easonable and also implies repeating aorta and primary branch
essel imaging whenever clinical symptoms or ﬁndings reveal new
vidence of LVV. US cannot evaluate the entirety of such a large vas-
ular territory. Another point to consider in regard to vessel imaging
s the relative value of regional vs entire aorta and branch vessel
tudies. In our Center for Vasculitis Care and Research, we are often
sked to see patients who have been repeatedly evaluated with
egional LV imaging. Such anatomically limited studies have the
isadvantage of not discovering new asymptomatic lesions which
ould signal inadequate therapy to achieve disease control. Lesions
nly become symptomatic when ﬂow is diminished to a critical
egree and compensatory ﬂow through collateral vessels becomes
hysiologically inadequate.
The GEFA assessment of biomarkers in GCA is both accurate
nd discouraging: . . .“there are no known speciﬁc biomarkers for
he diagnosis of GCA or for determining distinct disease pheno-
ypes or prognosis”. While acute phase reactants are helpful in
he assessment of disease activity, they lack speciﬁcity which is a
erious liability in an elderly population prone to numerous comor-
id conditions. A great deal of biomarker research has focused on
utoantibodies, cytokines and endothelial cell markers of injury
r activation. However, when one looks at the pathology of TAs
r LVV, the most striking sites of injury are within the media and
articularly within vascular smooth muscle cells (VSMC). It would
ppear that a more thorough evaluation of circulating proteins from
argeted tissue substrate, VSMCs, deserves further study.
Glucocorticoids have led to important reductions in GCA-
erived morbidity, especially relating to visual loss. In the absence
f randomized controlled studies of glucocorticoid use, clinical
rialists have selected initial dosing and tapering schedules by con-
ensus of experts. GEFA recommendations are in line with these,
s are the authors’ recommendations for the use of low dose ASA
barring contraindications) to diminish the risk of visual loss and
troke. A more controversial area is what to do for patients who
elapse once or repeatedly (50–91% of cases), as glucocorticoid
oses are tapered [7–9]. While the use of methotrexate (MTX) is
ndorsed in such cases, GEFA collaborators recognized that the efﬁ-
acy of MTX  in this setting is at best modest. Indeed, in cited studies
here were no signiﬁcant differences in the frequency of adverse
vents between groups, including those related to glucocorticoid
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use. The 3 studies from which recommendations are based included
161 patients [8–11]. MTX-induced pneumonitis did not occur and
pancytopenia was rarely seen. Nonetheless, given an elderly popu-
lation in whom gradual or more acute reductions in renal function
are common over time, potential life-threatening complications of
MTX  therapy are a serious concern. The ongoing randomized con-
trolled trial of tocilizumab and the recently reported association of
Varicella zoster virus with GCA [12] may  make these issues moot.
At present, I agree with the caution to not embrace tocilizumab
(or VZV) therapy for GCA until more complete efﬁcacy and toxicity
data are released.
Beyond the scope of this study but worthy of the readers’
consideration is the importance of anticipating and monitoring
patients with GCA for known glucocorticoid-induced morbidities
such as cataracts, glaucoma, osteoporosis, diabetes, and treatment-
induced or exacerbated hypertension and congestive heart failure.
These complications, which may  occur in over 85% of cases (more
than 3.3 times that of the general age-matched population) [1], may
also lead to diagnostic confusion with relapses (e.g. impaired vision,
constitutional complaints and cardiovascular events).
It is not easy for the general internist and even vasculitis spe-
cialists to digest and critically analyze the vast amount of data
presented and critiqued by the GEFA investigators. Indeed, their
recommendations are those of a large team of multidisciplinary
experts who  have given us an appreciation for existing controver-
sies, sound advice and a promise to revisit this exercise as new
discoveries yield greater clarity in the future.
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